Jackie Swinbourne’s Post

Providing a snapshot of FDB's PEGylation experience and capacity - from PD to commercial scale.

FibroBiologics is set to join the Russell 2000® Index effective July 1, 2024, according to a preliminary list of additions. This milestone reflects our growth and commitment to developing novel therapeutics using fibroblasts. Joining the #Russell2000 marks a significant step in increasing our visibility in the investment community and enhancing shareholder value. For more: https://bit.ly/4cHC6ST #Biotechnology #InvestmentGrowth

Coeptis Therapeutics is harnessing the potential of #cordblood-derived CD34+ cells. These therapies result in a potent #NKcell product for use as an off-the-shelf product ready for infusion when the patient needs it. https://bit.ly/3yqgU4G #Biotechnology

Researchers, how would you propose to progress drug delivery systems for the posterior inner eye segment? Your solutions should ensure sustained release over at least three months for diverse therapeutics ranging from low molecular weight compounds to complex molecules. Learn more on our open science platform #opnMe: https://lnkd.in/gEDjfkdd

Navigating the complexities of cell-based bioassays (CBBAs) is key to driving success in the development of advanced therapeutics. In this webinar, Jung-Hua YEH, PhD, Principal Scientist, and Reginald Clayton, PhD, Head of Biosafety and Deputy Site Head, will delve into: ✅ Method selection for different modalities, with a focus on potency ✅ Key considerations and common pitfalls in assay development ✅ A case study on potency assays for antibody-drug conjugates ✅ The importance of a two-way partnership to ensure efficiency and program success Don't miss this opportunity to learn from industry experts and keep your drug development programs on track. 📅 Register now: https://lnkd.in/eyM9dFZe #cbba #cellbasedbioassays #bioassays #drugdevelopment #celltherapies #genetherapies #atmps

Producing engineered extracellular vesicles for therapeutics applications: in this study, Kristin Luther, Joe Nabhan at Vesigen Therapeutics, Inc. and collaborators evaluated two scalable strategies for generating GFP-loaded ARMM-engineered EVs: transient transfection and stable cell line-based production. The upstream ARMM production processes used a suspension HEK293-derived line called 5B8 from Lonza, with production assessed in both shake flasks and bioreactors. For downstream ARMM purification, they employed Tangential Flow Filtration and Anion Exchange Chromatography https://lnkd.in/eWs8TfSM In vivo, ARMMs demonstrated rapid biodistribution, primarily to the spleen and liver, with lesser distribution to the kidneys and lungs. The successful scale-up of ARMM production highlights the potential of engineered EVs. An article also authored by Ali Navaei, Leah Gens, Carson Semple, Pearl Moharil, Ilaria Passalacqua, Komal Vyas, Qiyu Wang, Shu-Lin Liu, Lucy Sun, Senthil Ramaswamy and Davide Zocco #extracellularvesicles #exosomes #bioengineering #translationalmedicine #cellculture #Vesiculab

Rubbish in rubbish out! This is just one legacy piece of advice Martin Coldwell my legendary boss taught me at AstraZeneca Fit for purpose another nugget of gold from another legendary boss Jean Qiu. Conigen Bioscience, Inc. can help you remove the rubbish and create tools that will be fit for your biological research. #biologics #oncology #biotechnology

We are very grateful for the support from the European Commission - European Innovation Council and SMEs Executive Agency (EISMEA)  because is a huge impetus for Integra Therapeutics and our #FiCAT advanced therapies platform. Also, I am pleased to see that 21% of the companies chosen by #eicAccelerator are led by #women, which is an improvement over the previous call, although there is still room for improvement in the gender gap in #leadership positions in our sector. #EUeic #STEMWomen #WomenInBusiness #innovation #SocialImpact

#DYK: ~75% of disease-causing targets are located inside cells and most are still considered inaccessible? We believe we have discovered the solution to the fundamental challenges of intracellular therapeutics. Our proprietary EEV™ platform is designed to engage targets previously considered inaccessible and undruggable and has the potential to translate into substantial improvements in efficacy, safety and tolerability of future medicines. Learn more about our EEV™-therapeutics: https://lnkd.in/dcFuBP5F #Biotech #Oligonucleotides #EndosomalEscape

#DYK: ~75% of disease-causing targets are located inside cells and most are still considered inaccessible? We believe we have discovered the solution to the fundamental challenges of intracellular therapeutics. Our proprietary EEV™ platform is designed to engage targets previously considered inaccessible and undruggable and has the potential to translate into substantial improvements in efficacy, safety and tolerability of future medicines. Learn more about our EEV™-therapeutics: https://lnkd.in/dcFuBP5F #Biotech #Oligonucleotides #EndosomalEscape